Virtualització dels serveis d'una empresa

La virtualització és una tecnologia que permet l'abstracció del programari respecte dels recursos del maquinari, tant d'aplicacions com del sistema operatiu. Aquesta tecnologia està constantment en evolució, i el que fa pocs anys era un entorn de treball exclusiu per test de laboratori i aplicacions molt especifiques, ara permet oferir aplicacions i serveis d'entorns empresarials, permetent aprofitar el màxim els recursos disponibles. Aquest projecte tracta de plantejar la virtualització com a solució per a maximitzar el rendiments dels equips informàtics de una empresa. Introduirem la tecnologia de virtualització, planificarem la conversió dels serveis de l'empresa en màquines virtuals, detallarem els aspectes tècnics de la implementació i mostrarem els resultats d'aquesta virtualització.La virtualizacion es una tecnología que permite la abstracción del software respecto a los recursos de hardware, tanto a nivel de aplicaciones como de sistema operativo. Esta tecnología está en constante evolución, y lo que hace pocos años era un entorno de trabajo exclusivo para pruebas de laboratorio y aplicaciones muy especificas, ahora permite ofrecer aplicaciones y servicios de entornos empresariales, permitiendo aprovechar al máximo los recursos disponibles. Este proyecto trata de plantear la virtualización como una solución para maximizar el rendimiento de los equipos informáticos de una empresa. Introduciremos la tecnología de virtualización, planificares la conversión de los servicios de la empresa en máquinas virtuales, detallaremos los aspectos técnicos de la implementación y mostraremos los resultados de esta virtualización.Virtualization is a technology that allows to abstract software from the hardware resources, both for application and operating system. This technology is constantly evolving, in constant evolution, and what a few years ago was an workbench for laboratory test and very specific applications, now can offer applications and services for business and would maximize the hardware resources available. This project seeks to raise virtualization as a solution to maximize the performance of the hardware equipment of a company. Will introduce virtualization technology, plan how to convert the company's services in virtual machines, detail the technical implementation and show the results of this virtualization

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

DNA directed immobilization (DDI) for the development of an antibody fluorescent microarray for the determination of three family antibiotic residues in milk.

Misuse of antibiotics in food producing animals enhances the possibility to develop antibiotic resistance and can also lead to the appearance of these compounds in derivate products. New strategies to overcome this issue are required. In this context, the FoodSmartphone project will provide analytical tools to ensure food quality concerning pesticides, veterinary products or allergens, from farm to fork. The first approach is based on fluorescent microarrays which emerge as potential screening tools to determine the presence of multiple analytes at the same time. In this study, we present a multiplexed analytical platform based on hapten-oligonucleotide arrays to detect three families of antibiotics. The use of hapten-oligonucleotide conjugates allows the directed immobilization (DDI) of the signal for each antibiotic family by immobilizing the complementary oligo-probes over the surface of glass slide. After hybridization, the cocktail of primary antibodies is added in the samples and this binding is elucidated by the addition of secondary antibodies labeled to a fluorophore which provide the fluorescent signal. Using this system a group of penicillin, sulfonamides and tylosin can be quantified on buffer and milk samples. The format of this assay will provide the basis for its implementation on a Smartphone readout system

Virtualització dels serveis d'una empresa

La virtualització és una tecnologia que permet l'abstracció del programari respecte dels recursos del maquinari, tant d'aplicacions com del sistema operatiu. Aquesta tecnologia està constantment en evolució, i el que fa pocs anys era un entorn de treball exclusiu per test de laboratori i aplicacions molt especifiques, ara permet oferir aplicacions i serveis d'entorns empresarials, permetent aprofitar el màxim els recursos disponibles. Aquest projecte tracta de plantejar la virtualització com a solució per a maximitzar el rendiments dels equips informàtics de una empresa. Introduirem la tecnologia de virtualització, planificarem la conversió dels serveis de l'empresa en màquines virtuals, detallarem els aspectes tècnics de la implementació i mostrarem els resultats d'aquesta virtualització.La virtualizacion es una tecnología que permite la abstracción del software respecto a los recursos de hardware, tanto a nivel de aplicaciones como de sistema operativo. Esta tecnología está en constante evolución, y lo que hace pocos años era un entorno de trabajo exclusivo para pruebas de laboratorio y aplicaciones muy especificas, ahora permite ofrecer aplicaciones y servicios de entornos empresariales, permitiendo aprovechar al máximo los recursos disponibles. Este proyecto trata de plantear la virtualización como una solución para maximizar el rendimiento de los equipos informáticos de una empresa. Introduciremos la tecnología de virtualización, planificares la conversión de los servicios de la empresa en máquinas virtuales, detallaremos los aspectos técnicos de la implementación y mostraremos los resultados de esta virtualización.Virtualization is a technology that allows to abstract software from the hardware resources, both for application and operating system. This technology is constantly evolving, in constant evolution, and what a few years ago was an workbench for laboratory test and very specific applications, now can offer applications and services for business and would maximize the hardware resources available. This project seeks to raise virtualization as a solution to maximize the performance of the hardware equipment of a company. Will introduce virtualization technology, plan how to convert the company's services in virtual machines, detail the technical implementation and show the results of this virtualization

Mapping the human genetic architecture of COVID-19

The genetic make-up of an individual contributes to the susceptibility and response to viral infection. Although environmental, clinical and social factors have a role in the chance of exposure to SARS-CoV-2 and the severity of COVID-191,2, host genetics may also be important. Identifying host-specific genetic factors may reveal biological mechanisms of therapeutic relevance and clarify causal relationships of modifiable environmental risk factors for SARS-CoV-2 infection and outcomes. We formed a global network of researchers to investigate the role of human genetics in SARS-CoV-2 infection and COVID-19 severity. Here we describe the results of three genome-wide association meta-analyses that consist of up to 49,562 patients with COVID-19 from 46 studies across 19 countries. We report 13 genome-wide significant loci that are associated with SARS-CoV-2 infection or severe manifestations of COVID-19. Several of these loci correspond to previously documented associations to lung or autoimmune and inflammatory diseases3–7. They also represent potentially actionable mechanisms in response to infection. Mendelian randomization analyses support a causal role for smoking and body-mass index for severe COVID-19 although not for type II diabetes. The identification of novel host genetic factors associated with COVID-19 was made possible by the community of human genetics researchers coming together to prioritize the sharing of data, results, resources and analytical frameworks. This working model of international collaboration underscores what is possible for future genetic discoveries in emerging pandemics, or indeed for any complex human disease

Searches for the ZγZ\gamma decay mode of the Higgs boson and for new high-mass resonances in pppp collisions at s=13\sqrt{s} = 13 TeV with the ATLAS detector

International audienceThis article presents searches for the Zγ decay of the Higgs boson and for narrow high-mass resonances decaying to Zγ, exploiting Z boson decays to pairs of electrons or muons. The data analysis uses 36.1 fb$^{−1}$ of pp collisions at $\sqrt{s}=13$ recorded by the ATLAS detector at the CERN Large Hadron Collider. The data are found to be consistent with the expected Standard Model background. The observed (expected — assuming Standard Model pp → H → Zγ production and decay) upper limit on the production cross section times the branching ratio for pp → H → Zγ is 6.6. (5.2) times the Standard Model prediction at the 95% confidence level for a Higgs boson mass of 125.09 GeV. In addition, upper limits are set on the production cross section times the branching ratio as a function of the mass of a narrow resonance between 250 GeV and 2.4 TeV, assuming spin-0 resonances produced via gluon-gluon fusion, and spin-2 resonances produced via gluon-gluon or quark-antiquark initial states. For high-mass spin-0 resonances, the observed (expected) limits vary between 88 fb (61 fb) and 2.8 fb (2.7 fb) for the mass range from 250 GeV to 2.4 TeV at the 95% confidence level

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

10.1161/CIRCULATIONAHA.118.038840CIRCULATION1402103-11